JP4043953B2 - ｍＧｌｕＲ２アンタゴニストＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体 - Google Patents

ｍＧｌｕＲ２アンタゴニストＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体 Download PDF

Info

Publication number
JP4043953B2
JP4043953B2 JP2002581420A JP2002581420A JP4043953B2 JP 4043953 B2 JP4043953 B2 JP 4043953B2 JP 2002581420 A JP2002581420 A JP 2002581420A JP 2002581420 A JP2002581420 A JP 2002581420A JP 4043953 B2 JP4043953 B2 JP 4043953B2
Authority
JP
Japan
Prior art keywords
phenyl
dihydro
benzo
diazepin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002581420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525965A (ja
JP2004525965A5 (enExample
Inventor
アダム，ゲオ
ゲッチ，エルヴィン
ミュッテル，ヴァンサン
ヴィッヒマン，ユルゲン
ヴォルテリング，トーマス・ヨハネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004525965A publication Critical patent/JP2004525965A/ja
Publication of JP2004525965A5 publication Critical patent/JP2004525965A5/ja
Application granted granted Critical
Publication of JP4043953B2 publication Critical patent/JP4043953B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002581420A 2001-04-12 2002-04-02 ｍＧｌｕＲ２アンタゴニストＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体 Expired - Fee Related JP4043953B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109126 2001-04-12
PCT/EP2002/003643 WO2002083665A1 (en) 2001-04-12 2002-04-02 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I

Publications (3)

Publication Number Publication Date
JP2004525965A JP2004525965A (ja) 2004-08-26
JP2004525965A5 JP2004525965A5 (enExample) 2005-07-28
JP4043953B2 true JP4043953B2 (ja) 2008-02-06

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002581420A Expired - Fee Related JP4043953B2 (ja) 2001-04-12 2002-04-02 ｍＧｌｕＲ２アンタゴニストＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体

Country Status (37)

Country Link
US (1) US6548495B2 (enExample)
EP (1) EP1379522B1 (enExample)
JP (1) JP4043953B2 (enExample)
KR (1) KR100566178B1 (enExample)
CN (1) CN1268626C (enExample)
AR (1) AR035456A1 (enExample)
AT (1) ATE287883T1 (enExample)
AU (1) AU2002310912B2 (enExample)
BG (1) BG108253A (enExample)
BR (1) BR0208887A (enExample)
CA (1) CA2441771C (enExample)
CZ (1) CZ20033002A3 (enExample)
DE (1) DE60202761T2 (enExample)
DK (1) DK1379522T3 (enExample)
EC (1) ECSP034796A (enExample)
ES (1) ES2235044T3 (enExample)
GT (1) GT200200072A (enExample)
HR (1) HRP20030791B1 (enExample)
HU (1) HUP0400991A3 (enExample)
IL (2) IL158021A0 (enExample)
JO (1) JO2273B1 (enExample)
MA (1) MA27011A1 (enExample)
MX (1) MXPA03009317A (enExample)
MY (1) MY130369A (enExample)
NO (1) NO325300B1 (enExample)
NZ (1) NZ528345A (enExample)
PA (1) PA8543201A1 (enExample)
PE (1) PE20021072A1 (enExample)
PL (1) PL367086A1 (enExample)
PT (1) PT1379522E (enExample)
RU (1) RU2270197C2 (enExample)
SI (1) SI1379522T1 (enExample)
SK (1) SK13692003A3 (enExample)
UY (1) UY27259A1 (enExample)
WO (1) WO2002083665A1 (enExample)
YU (1) YU79103A (enExample)
ZA (1) ZA200307242B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779874B2 (en) 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives
PL1651234T3 (pl) * 2003-07-25 2008-02-29 Hoffmann La Roche Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
EP1812392B1 (en) 2004-11-05 2008-07-09 F.Hoffmann-La Roche Ag Process for preparation of isonicotinic acid derivatives
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
MX2009010729A (es) * 2007-04-19 2009-10-26 Hoffmann La Roche Derivados de dihidro-benzo[b] [1,4]diazepin-2-ona-sulfonamida.
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
BRPI0816970A2 (pt) * 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
HK1206615A1 (en) 2012-10-23 2016-01-15 霍夫曼-拉罗奇有限公司 Mglu2/3 antagonists for the treatment of autistic disorders
KR102190597B1 (ko) * 2013-02-28 2020-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 테트라하이드로이미다조[1,5-d][1,4]옥사제핀 유도체
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX2016013711A (es) 2014-04-23 2017-01-13 Hoffmann La Roche Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
AU6420700A (en) * 1999-08-05 2001-03-05 Prescient Neuropharma Inc. Novel 1,4-benzodiazepine compounds and derivatives thereof
TR200201023T2 (tr) * 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
AU779874B2 (en) * 1999-10-15 2005-02-17 F. Hoffmann-La Roche Ag Benzodiazepine derivatives

Also Published As

Publication number Publication date
NO325300B1 (no) 2008-03-25
IL158021A (en) 2010-04-15
YU79103A (sh) 2006-05-25
HUP0400991A3 (en) 2009-06-29
ZA200307242B (en) 2004-12-16
HK1068339A1 (en) 2005-04-29
PA8543201A1 (es) 2002-10-31
AR035456A1 (es) 2004-05-26
JP2004525965A (ja) 2004-08-26
NZ528345A (en) 2005-04-29
CN1522252A (zh) 2004-08-18
NO20034496L (no) 2003-10-08
HUP0400991A2 (hu) 2004-08-30
IL158021A0 (en) 2004-03-28
DE60202761D1 (de) 2005-03-03
ATE287883T1 (de) 2005-02-15
EP1379522A1 (en) 2004-01-14
MA27011A1 (fr) 2004-12-20
CA2441771C (en) 2008-12-30
CZ20033002A3 (cs) 2004-03-17
ES2235044T3 (es) 2005-07-01
SI1379522T1 (en) 2005-04-30
NO20034496D0 (no) 2003-10-08
UY27259A1 (es) 2002-10-31
KR20030088502A (ko) 2003-11-19
HRP20030791B1 (en) 2006-06-30
US20020198197A1 (en) 2002-12-26
HRP20030791A2 (en) 2005-06-30
RU2003130648A (ru) 2005-04-10
PL367086A1 (en) 2005-02-21
BR0208887A (pt) 2004-06-29
RU2270197C2 (ru) 2006-02-20
CN1268626C (zh) 2006-08-09
BG108253A (bg) 2005-03-31
PE20021072A1 (es) 2002-12-07
MXPA03009317A (es) 2004-02-12
GT200200072A (es) 2003-06-19
AU2002310912B2 (en) 2005-06-16
SK13692003A3 (sk) 2004-05-04
DK1379522T3 (da) 2005-05-30
KR100566178B1 (ko) 2006-03-29
DE60202761T2 (de) 2006-01-12
JO2273B1 (en) 2005-04-07
MY130369A (en) 2007-06-29
ECSP034796A (es) 2003-12-01
EP1379522B1 (en) 2005-01-26
CA2441771A1 (en) 2002-10-24
WO2002083665A1 (en) 2002-10-24
PT1379522E (pt) 2005-05-31
US6548495B2 (en) 2003-04-15

Similar Documents

Publication Publication Date Title
EP1379522B1 (en) DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
EP1379511B1 (en) DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
AU2002310912A1 (en) Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mGluR2 antagonists I
AU2002312788A1 (en) Dihydro-benzo [b] [1, 4] diazepin-2-one derivatives as mGluR2 antagonists II
NO327817B1 (no) ``Benzodiazepin-derivater, deres fremstilling, medikament inneholdende slike samt anvendelse av disse for fremstilling av medikament for behandling av sykdom``
CZ20021663A3 (cs) Nové deriváty benzodiazepinu
RU45093U1 (ru) Пылеуловитель

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071114

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111122

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121122

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121122

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131122

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees